Elvina Almuradova: ROSELLA Phase III – Adding Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on X:
“ROSELLA Phase III: Adding relacorilant to nab-paclitaxel in platinum-resistant ovarian cancer:
PFS: 6.5 vs 5.5 mo (HR 0.70; p=.0076)
OS (interim): 16 vs 11.5 mo (HR 0.69; p=.0121)
A promising new standard?”
Title: Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
Authors: Alexander B Olawaiye, Laurence Gladieff, David M O’Malley, Jae-Weon Kim, Gabriel Garbaos, Vanda Salutari, Lucy Gilbert, Linda Mileshkin, Alix Devaux, Elizabeth Hopp, Yong Jae Lee, Ana Oaknin, Mariana Scaranti, Byoung-Gie Kim, Nicoletta Colombo, Michael E McCollum, Connie Diakos, Andrew Clamp, Aliza L Leiser, Boglárka Balázs, Bradley J Monk, Giuseppa Scandurra, Emily McClung, Emilie Kaczmarek, Brian Slomovitz, Helena De La Cueva, Aknar Freire de Carvalho Calabrich, Chiara Cassani, Benoit You, Toon Van Gorp, Cristina Churruca, Giuseppe Caruso, Shibani Nicum, Andrea Bagaméri, Grazia Artioli, Lubomir Bodnar, Sokbom Kang, Ignace Vergote, Amanda Kesner-Hays, Hristina I Pashova, Sachin G Pai, Iulia Cristina Tudor, Adrian M Jubb, Domenica Lorusso
You can read the Full Article on The Lancet Journal
More posts featuring Elvina Almuradova.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023